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FOREWORD
The authors are to be congratulated on producing this much needed and comprehensive 
guideline which should improve the care and experience of inpatients with diabetes treated 
by subcutaneous insulin infusion (CSII) pump therapy.  Though multi-professional it has 
been produced with a high level of user involvement ensuring that the guideline is firmly 
grounded in patient experience. It will be of great value to diabetes inpatient teams as well as 
to the large variety of other health care professionals who care for this group of inpatients. 
Insulin pump therapy in the UK is almost exclusively confined to people with type 1 
diabetes of which 10-15% are treated by CSII. Only 7% of the in-patient diabetic population 
has type 1 diabetes thus, at most only 1% of inpatients with diabetes are treated with 
CSII. Over 90% are admitted for a variety of non-diabetes related reasons and as such 
they will be primarily under the care of non-diabetes specialist teams with little or no 
experience of insulin pump therapy. Indeed, given the rarity of this group most healthcare 
professionals will not have seen an insulin pump and almost certainly not be familiar 
with all of the many different pumps and ‘pods’. Under these circumstances non-specialist 
will often discontinue pump therapy in favour of familiar therapies such as variable rate 
intravenous insulin infusion or intermittent boluses of subcutaneous insulin much to the 
frustration of patients particularly if this destabilises their glucose control. Furthermore, 
the return to pump therapy can be tricky often prolonging the inpatient stay.  
This guidance supports the continued use of CSII during the inpatient stay and where 
appropriate encourages health care professionals to allow the person with diabetes to manage 
their own pump therapy. The most important messages are the early involvement of the 
inpatient diabetes team in all scenarios and the recognition that most pump users are more 
than capable of managing their insulin pump therapy provided they are well enough to do so. 
The document highlights what can go wrong and what to look out for to prevent harms 
from happening. It also addresses for both specialists and non-specialists common but 
not often considered scenarios such as what to do with the pump during MRI scanning, 
safe disconnection from the pump, insulin therapy during the pump free period, 
managing hypoglycaemia on insulin pump therapy, safe storage of a removed pump and 
safe re-establishment of pump therapy. There is increasing use of CSII in pregnancy 
as its benefits are being increasingly recognised. In this context there is a very useful 
section on CSII in pregnancy including during steroid treatment and in labour.
I have no doubt that this comprehensive guideline will be welcomed by health 
care professionals and patients as it will help promote improvements in the care, 
outcomes and experience of people with diabetes on insulin pump therapy. 
Professor Gerry Rayman
Consultant Diabetologist, Ipswich Hospital NHS Trust
Clinical Lead of the National Diabetes Inpatient Audit 
Co-Lead for the Diabetes GIRFT project, NHS I
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1. STATEMENT, IMPLEMENTATION AND AUDIT
Continuous subcutaneous insulin infusion (CSII, Insulin pump) therapy is used by 10-15% of people with type 
1 diabetes, and by some patients with type 2 diabetes. It is an effective option for day to day insulin delivery, 
but one that may not be familiar to health care professions caring for these people in an in-patient hospital 
setting. Therefore, patients on CSII therapy are often unnecessarily switched to alternative modes of insulin 
delivery on admission to hospital, or alternatively, CSII therapy maybe mismanaged. 
There are currently no national level guidelines for the inpatient management of CSII in the UK. 
These guidelines are designed to support the in-patient care of people with type 1 diabetes managed on CSII therapy. 
They were developed by a multi-disciplinary group of health care professionals and a patient on behalf of the 
Diabetes Technology Network and the Association of British Clinical Diabetologists. It has been further reviewed by 
national diabetes societies. It conforms to other national guidelines for diabetes / pregnancy care.
It is intended that the guideline will be useful to clinicians and service commissioners in planning, organising 
and delivering high quality diabetes inpatient care. There remains, however, an individual responsibility of 
healthcare professionals to make decisions appropriate to the circumstance of the individual patient. When 
implementing this guideline full account should be taken of the local context and in line with statutory 
obligations required of the organisation and individual. 
These guidelines will be next reviewed in September 2018.
Quality Indicators
 o Every Trust should have a local management plan 
in place based on these or other authoritative 
guidelines. These guidelines should be current and 
should not be used if the review date has expired.
 o Every Trust should have a health care professional 
leading the implementation of these guidelines, and 
performance indicators should be used to assess the 
quality of care given.
 o The purpose of standards are to maximise patient 
safety, improve patient satisfaction, support best 
clinical practice, reduce cost to the Trust relating 
to litigation and complaints, and contribute to 
reduced length of stay.
 o Performance indicators will include 
 - adverse events relating to insulin pump use 
(hypoglycaemia, DKA)
 - delayed discharge due to conversion  
onto/off CSII
 - patient satisfaction with inpatient management 
of CSII therapy
 - ‘loss’ of insulin pumps removed from patients
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2. OVERVIEW OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) THERAPY
Continuous subcutaneous insulin infusion (CSII, also 
known as ‘insulin pumps’) are used by people with 
type 1 diabetes(T1DM) (and some with type 2 diabetes) 
to improve glucose control and/or reduce the risk of 
hypoglycaemia.1,2 Modern CSII are portable and discrete, 
and utilise smart technologies, such as bluetooth 
transmission of capillary glucose level from glucometer 
to CSII, and the ability to download CSII data to a 
computer for analysis. Examples of commonly used 
‘pumps’ are provided in Appendix 4. Contrary to the 
hopes of many individuals with T1DM, CSII is not a fully 
automatic “artificial pancreas”, and therefore requires a 
high level of user involvement.
How it works
CSII involves a continuous basal infusion of short 
acting insulin (the hourly rate typically varies over a 24 
hour period), in combination with meal-time boluses 
of the same insulin. Both basal and bolus insulin are 
delivered by CSII, which infuses insulin through a 
catheter (tubing), or directly via a pod. Both the tubing 
and pod attach to a fine bore subcutaneous cannula. 
The cannula is typically sited in the abdomen, though 
other sites (arms, legs, buttocks) can also be used, and 
is changed every 2-3 days. Any short acting insulin 
can be used (Novorapid/insulin aspart, Humalog/
insulin lispro, Apidra /insulin glulisine, Fiasp/ faster 
acting insulin aspart/). The basal infusion rate is pre-
programmed by the patient (or their diabetes specialist 
team) and will continue to run until the insulin 
cartridge is empty. The basal rates can be temporarily 
increased/decreased to accommodate fluctuations in 
blood glucose levels e.g. as a consequence of increased 
activity, or ill health. Boluses are delivered under 
the patient’s direction, to cover carbohydrate intake 
and to correct for high blood glucose levels. Most 
CSII users make use of an inbuilt ‘bolus calculator’, 
which utilises known variables for that individual 
(insulin:carbohydrate ratio, insulin sensitivity and 
target blood glucose range) in conjunction with 
situation-specific data (current capillary glucose level, 
estimated carbohydrate intake and time since last 
insulin bolus). Some CSII work in conjunction with 
a continuous glucose sensor to temporarily suspend 
insulin delivery if hypoglycaemia is developing.
What can go wrong
People on CSII do NOT take any long acting insulin so if 
there is any interruption to insulin delivery (e.g. if the 
cannula is blocked/dislodged/removed) hyperglycaemia 
and then ketoacidosis can develop very quickly. 
In these situations, the problem has to be identified 
and rectified, e.g. by re-siting the cannula, changing 
the tubing, or starting alternative insulin such as an 
intravenous infusion. Technical problems can occur; the 
CSII manufacturing companies offer round-the-clock 
telephone support and are typically able to provide a 
replacement pump within 24hrs if required. All patients 
using CSII are advised to retain a supply of their pre- 
CSII insulin pens for use in an emergency situation, for 
example, in case of ‘pump failure’ or damage.
The CSII user in hospital
Unless incapacitated, most people using CSII are 
safest remaining on CSII if admitted to hospital. 3
If he/she is unable to manage the CSII, and no specialist 
advice is immediately available, remove CSII and 
start a conventional intravenous insulin infusion or 
S/C basal-bolus insulin regimen. CSII is expensive 
and steps should be taken to ensure they are not lost 
when a patient is admitted to hospital. CSII should 
only be adjusted by its owner (who has received 
extensive training) or a member of the Diabetes team in 
possession of the correct knowledge and skills.4
Please discuss all CSII patients with a member of the 
diabetes team
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3. CSII MANAGEMENT FOR DKA AND THE UNCONSCIOUS/INCAPACITATED PATIENT
 q See appendix 1 for summary
It is usually best for the patient to continue to self-manage their diabetes with CSII except:
• If unconscious, confused or incapacitated e.g. if illness/pain prevents self-management
• If undergoing major procedures under General Anaesthetic lasting >2 hours
• Diabetic ketoacidosis (DKA)
Blood sugar above 14
Check pump and infusion set
Test for ketones
No ketones
Give correction 
bolus with CSII
Check sugar 2 h later
If sugar still above 11 give 
second correction bolus 
with syringe or pen
Look for cause of high 
sugar and change cannula, 
tube and insulin cartridge.
Check sugar 2 h later. Do not 
go to bed until sugar normal
Ketones present
Double correction 
bolus and administer 
with pen or syringe
Drink plenty of water
Look for cause of high 
sugar and change cannula, 
tube and insulin cartridge.
No ketones Ketone still present
Double correction bolus and 
administer via pen or syringe
Inform doctor or diabetes 
specialist nurse. 
Contact GP/A&E if 
vomiting occurs
The unconscious or incapacitated patient
If patient unable to self-manage their CSII: detach pump 
and tubing. Place pump in a safe place and document. 
This is the ideal because it allows the diabetes team 
to subsequently ‘interrogate’ and adjust the pump. 
Alternatively, ask a relative to take the pump home 
for safekeeping. Immediately start alternative insulin 
e.g. variable rate IV insulin (refer to local guidelines) 
or subcutaneous insulin (see below: “alternatives to 
CSII”) unless hypoglycaemic. If hypoglycaemic, start 
alternative insulin once hypoglycaemia is treated. CSII 
can be restarted once patient recovered (see below: 
“stopping and restarting CSII”).
Diabetic ketoacidosis (DKA):
The altered tissue perfusion in DKA affects insulin 
absorption, making CSII unreliable. CSII should be 
temporarily discontinued in patients presenting in 
DKA: remove cannula/detach pump/pod. For further 
management, follow standard DKA protocol. CSII can 
be restarted once DKA is treated (see below: “stopping 
and restarting CSII”).  All patients should have 
specialist diabetes input before discharge to review 
CSII settings which may need adjusting to prevent 
subsequent DKA and to re-enforce “sick day rules”.
Managing high glucose levels 
Patients admitted to hospital often have elevated blood 
glucose levels due to illness and stress. They should use 
their standard ‘Sick Day Rules’ to manage these glucose 
values. If they do not have their own system, or are 
too unwell to manage them, then a simple algorithm is 
outlined across
Sick Day Rules’ algorithm for managing 
high blood sugar on CSII5
Check sugar and ketones 
1 to 2 hours later
© British Journal of Anaesthesia
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4. CSII AND RADIOLOGY INVESTIGATIONS
Current manufacturers guidelines state that CSII 
must be suspended and removed along with any metal 
cannulae prior to prior to MRI, CT scan, X Ray or any 
other type of exposure to radiation, and should not be 
taken into the scanning room. However it is likely that 
some of this advice is based on lack of evidence rather 
than evidence of harm. Therefore these guidelines 
should be individualised by each centre. Many centres 
continue the use of CSII for non magnetic imaging 
such as X Ray, and CT scans. 
The patient should reconnect CSII immediately 
following any radiological investigation. CSII can be 
safely suspended/removed for up to an hour at a time 
without needing alternative insulin. A correction bolus 
may be needed on reconnecting the pump (see page 10: 
Stopping and re-starting CSII).
5. CSII MANAGEMENT FOR SURGERY
 q See appendix 2 for summary
Fasting is not usually a problem for CSII users, so being 
“nil by mouth” does not necessarily mean removal of 
CSII or need for IV insulin.6 Most patients will be able to 
manage their CSII post sedation/anaesthesia as safely 
as any patient using standard insulin pen injection 
therapy, and are more likely to achieve stable glucose 
control. Hence it is not necessary to admit day-case 
patients overnight for variable rate IV insulin infusion 
simply because they manage their diabetes by CSII. 
However, some patients will feel unable to self-manage 
post-procedure and should discuss this with their 
diabetes team in advance; they may require alternative 
management such as prior conversion back to insulin 
pens (see below: “alternatives insulin regimens”), or 
hospital admission. If continuing on CSII, patients 
should ensure SC CSII cannula is sited away from 
operative site and accessible to healthcare team. 
Major surgical procedures (>2 hours duration, 
or where they are likely to miss more than 
one meal, or surgery requiring diathermy): 
Patient should remove their CSII for these procedures, 
and this should be stored safely. Once CSII removed, start 
variable rate IV insulin infusion immediately (refer to local 
guidelines ). CSII can be restarted once patient recovered 
and able to manage it (see: “stopping and restarting CSII”). 
Minor procedures (<2 hours and expected to eat/drink 
within 2-3hrs) under general anaesthetic or sedation:
Patient should ensure blood glucose is in the acceptable 
range pre-procedure i.e. ideally 6-10mmol/l, but 4-12 
acceptable with more frequent testing. If glucose 
is not in the acceptable range, then one round of 
bolus correction via the CSII is allowed before 
starting variable rate IV insulin (as for major surgical 
procedures). Whilst on CSII (or VRII), the healthcare 
team must monitor patient’s capillary glucose levels at 
least hourly; Post procedure, the patient on CSII should 
also use a correction bolus if capillary glucose >10 
mmol/l. Consider starting VRII if BG > 12mmol/l.7
If the CSII alarms during the procedure, do not attempt to 
rectify; monitor blood glucose every 30 mins and start IV 
insulin if >12mmol/l. If the CSII alarm becomes intrusive, 
remove CSII plus cannula, allow CSII to continue to run 
(the amount of insulin “lost” is minimal) and store safely.
If VRII used during procedure, see below for transferring 
back to CSII (“stopping and restarting CSII”); a correction 
bolus is less likely to be required in this situation.
Minor procedures without sedation:
The CSII can be continued with regular glucose 
monitoring as for any person with diabetes.
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6. CSII MANAGEMENT FOR PREGNANT WOMEN 
 q See appendix 3 for summary
Introduction
The goal of insulin therapy in diabetes management 
during pregnancy is to maintain blood glucose levels 
as close to normal as possible in order to improve the 
outcome of pregnancy and reduce the risk to both 
mother and baby.  The aim of glycaemic control for 
delivery is to safely maintain near-normal glucose levels 
until delivery and to safely manage the transition to 
post-delivery when insulin requirements fall and there 
is an increased  risk of hypoglycaemia.8
Antenatal and postpartum Care
Obstetric care will follow established protocols 
for patients with diabetes. The diabetes team are 
responsible for CSII management including glycaemic 
control and addressing any educational needs.
Inpatient use of CSII
Please inform the Diabetes Specialist antenatal team 
of any pregnant woman using CSII therapy admitted 
to hospital. 
CSII may continue providing the patient or partner is 
able to self-manage the CSII and perform the required 
blood monitoring.
Inpatient use of steroids during Pregnancy
• Please inform the Diabetes Specialist antenatal team 
before (or as soon as possible after) steroids are started. 
• CSII may continue. The Diabetes Specialist antenatal 
team will instruct the patient regarding any change 
in CSII settings. A temporary increase in basal rate 
of 30% or more may be required, and needs to be 
individualised based on patient requirements
• Patients will be responsible for the management of 
CSII and glucose testing.
• Patients will be required to test their glucose levels 
1-2 hourly; levels of 4- 7.8mmol/L should be aimed for.
• If glycaemic targets are not achieved, Midwifery or 
obstetric staff should contact a DSN or Diabetes 
Consultant. Consider commencing VRII (without 
IV glucose).  This should be prescribed in advance 
where possible. Note: CSII may be continued 
alongside VRII in this situation.
Managing glycaemic control through delivery 
in women with Type 1 Diabetes on CSII 
Women on CSII may be converted to VRII plus glucose for 
delivery (traditional management).  Woman who chose,  
may continue to use their CSII through delivery, provided 
their blood glucose levels are within the target range of 
4 – 7 mmol/L and patient/partner able to manage their 
CSII. The decision regarding the patient’s suitability to 
self-manage CSII through delivery will be made by the 
diabetes specialist antenatal team and documented in the 
patient’s case sheets. The diabetes team will educate the 
woman and her partner, and provide written instructions, 
regarding cannula siting, guidelines for using CSII through 
delivery, and situations where CSII treatment may need to 
be discontinued and traditional management instigated 
with VRII plus IV glucose. The individualised VRII should 
be prescribed in advance. 
Staff responsibilities 
While the woman remains on CSII, the patient and her 
partner are responsible for checking glucose hourly, 
giving corrections via CSII, adjusting basal rates and 
other pump settings as required including at delivery.  
The midwife is responsible for ensuring the patient/
partner remains able and willing to manage their CSII, 
that glucose is checked and documented hourly, and 
that if glucose is persistently (see below) above 7mmol/l, 
VRII plus IV glucose is started and the CSII stopped. 
Once the patient is on VRII plus glucose, the midwife is 
responsible for checking glucose hourly and adjusting 
VRII rates as prescribed. 
Protocol for managing glycaemic 
control through delivery using CSII
Measure and record blood glucose levels hourly using 
approved hospital blood glucose meter. The patient 
should continue her usual basal infusion rates, aiming 
to keep blood glucose levels between 4 - 7mmol/L. Bolus 
correction doses should be made by the patient via CSII 
to maintain target blood glucose levels 4 to 7mmol/l. 
If patient/partner unable to manage CSII, or if blood 
glucose >7mmol/l for >2 hours despite correction doses, 
switch from CSII to individualised VRII plus IV glucose.  
(Remove CSII and tubing and place in suitable container; 
no need to turn off CSII nor to remove SC cannula) 
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Correction doses during labour: 
If blood glucose greater than 7mmol/l, a correction bolus 
dose should be given via CSII, aiming for a blood glucose 
of 5mmol/l, using the patient’s personal correction factor 
(also known as “ISF” = insulin sensitivity factor) or if not 
known, calculate 1 unit of insulin to reduce blood glucose 
levels by 2.5mmol/l e.g. if blood glucose 10.0 mmol/l, 
give 2 units bolus. After 1 hour, if that correction bolus 
is ineffective i.e. blood glucose still above 7.0 mmol/l, 
another correction bolus dose should be given via CSII 
(using the same calculation advice as above). After a 
further ½ hour, if blood glucose levels still not below 7.0 
mmol/l, then switch to VRII plus IV glucose  as above. 
Hypoglycaemia during labour: 
If blood glucose < 4.0mmol/l, treat hypoglycaemia as 
per hospital policy. If the woman has one unexplained 
hypoglycaemic event, she should reduce her current 
basal rate by 25 - 50% using a temporary basal rate 
setting. If having further episodes of hypoglycaemia 
despite original reduction, she should reduce by another 
25% or more as required. A lower basal rate is usually 
required throughout the rest of labour. After delivery, 
the basal rate should change to the post-delivery  basal 
rate which should have been defined. 
Post-delivery 
Planned post-delivery CSII settings should be 
determined towards the end of pregnancy, in 
conjunction with the diabetes team, and documented.  
The basal profile is typically the same as pre-pregnancy 
basal profile often with a 10-20% reduction, or if CSII 
started during pregnancy, 50% of pre-delivery basal 
rates. This post-delivery  basal profile can be entered 
into the pump memory in advance.  The planned post-
delivery insulin:carbohydrate ratio, ISF and targets will 
need to be programmed after delivery but before the 
first bolus dose.  
If there is no documentation of post partum doses 
then the basal rate can be set to 0.5 units/hour, insulin: 
carbohydrate ratio 1:15g, insulin sensitivity factor 
4mmol/L, and BG targets 6-8mmol/L. These should be 
reviewed and adjusted in conjunction with the diabetes 
specialist team before discharge
If the women continues on CSII for delivery, the basal 
rate should be changed to the planned post-delivery 
basal rate immediately at delivery and the bolus 
calculator settings changed as soon as possible but 
before the first bolus dose.  
If managed with VRII, CSII can be recommenced once 
the patient is able to self-manage the pump. Ensure all 
pump settings are changed to post-delivery settings as 
above.  The VRII should continue for 60 minutes after 
restarting CSII.
For women who are breastfeeding, settings may need 
reducing by a further 10-20% or even more as feeding 
 is established. 
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7. HYPOGLYCAEMIA IN PATIENTS ON CSII 
8. STOPPING AND RE-STARTING CSII 
Patients able to manage their CSII:
Treat hypoglycaemia according to local protocol, and 
this is likely to include rapid acting carbohydrates (e.g. 
dextrose tablets). Unlike patients on long acting insulin, 
follow-up with long acting carbohydrates is not usually 
needed. CSII infusion rates may need adjustment, 
especially if history of recurrent hypoglycaemia: consult 
diabetes team. 
The unconscious/incapacitated patient:
Initial treatment of hypoglycaemia is as standard local 
protocol. If persistent hypoglycaemia occurs, remove 
cannula and pump. Once normoglycaemic, re-start 
insulin, either CSII if patient now alert and able to 
self-manage, or alternative regimen (see below); this is 
needed to prevent the development of ketoacidosis. 
Stopping: 
The pump together with its tubing may be removed 
leaving only the SC cannula in place, unless cannula site 
is infected or in surgical field. Clearly this will not apply 
to CSII without external tubing such as the Omnipod®. 
It is important not to cut tubing or disconnect the pump 
from the tubing as the remaining insulin in the tube 
may infuse quickly risking hypoglycaemia. Place the 
CSII into a suitable container and do not attempt to 
turn off; the amount of insulin “lost” into the container 
will be minimal. Document where the CSII is stored, 
or to whom it has been given. The insulin in a CSII is 
very short acting therefore alternative insulin must be 
started immediately i.e. within an hour (see below) to 
avoid risk of ketoacidosis.  If the patient is able to do so, 
he/she should make a record of their current basal and 
bolus settings, as this data may be lost if the pump is 
stopped for any significant length of time.
Restarting: 
The person with diabetes is ideally best placed to restart 
the CSII because they will have received training in this 
process and will be experienced. If this is not possible, and 
CSII has been only temporarily removed or suspended (i.e. 
no IV insulin infusion has been required) and SC cannula 
still in position, patient should perform a “fixed prime” 
to refill the dead space within the tubing, then simply 
reconnect CSII, and restart basal infusion. If capillary 
glucose >10mmol/l, he/she should bolus a correction dose 
once CSII re-connected, using their personal correction 
ratio or ISF (insulin sensitivity factor).  
If transferring from IV insulin infusion: ask patient to 
insert new cannula and re-start CSII after performing a 
fixed prime (there is no need to wait until a meal); wait 
60 minutes before discontinuing IV insulin. 
If transferring from subcutaneous insulin: patient 
inserts new cannula, performs a fixed prime and 
re-starts CSII. CSII settings may need to be re-
programmed. Patient may need to temporarily reduce 
background insulin infusion rate (e.g. drop to a 70% 
temporary basal rate for 24hrs) while long acting 
subcutaneous insulin is still active - increased glucose 
monitoring may be required. No further subcutaneous 
insulin doses should be required once CSII restarted. 
Re-check blood glucose 1-2 hours after CSII re-start. 
Contact diabetes team for further advice.
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All the guidance below should be used in 
accordance with local guidelines and protocols:
The appropriate alternative insulin regimen depends on 
the clinical scenario:
• For patients with DKA, use a fixed rate IV insulin 
infusion as per local guidelines. 
• For patients who are fasted and/or have unstable 
glucose levels (but not DKA), use aVRII as per  
local guidelines.
• For patients who are unable to self-manage their 
CSII, but do not have unstable blood glucose levels 
and are not NBM, a basal-bolus insulin regimen is 
preferable to VRII. 
9. ALTERNATIVE INSULIN REGIMENS FOR HOSPITALISED PATIENTS UNABLE TO CONTINUE ON CSII 
How to calculate multiple daily injection insulin requirements
Calculate appropriate starting doses based on the patient’s recent (e.g. 7day) average total daily insulin dose 
(TDD); this information can be obtained by the patient or DSN from the pump. 
• Prescribe 50% of the TDD as Levemir insulin (as per NICE guidelines), initially split equally in a bd  
insulin regime 
• For meal-time (rapid acting) insulin dose: 50% of TDD/ 3 plus a safety adjustment (e.g. minus 30%) to 
minimise risk of hypoglycaemia. Titrate doses according to response. Alternatively, if the patient is able to 
continue to carbohydrate count, prescribe a variable dose for self-administration. 
• E.g. a patient’s average CSII insulin TDD for last 7 days is 48 units/day.  50% of 48 units = 12 units bd daily 
Levemir® insulin. 50% of 48units/3 = 8 units of rapid acting insulin with each meal: after safety adjustment 
= 6 units. If the patient is trained in carbohydrate counting (and they often are), it would be preferable for 
them to inject insulin doses according to their insulin : carbohydrate ratio.
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APPENDIX 1: EMERGENCY ADMISSIONS AND CSII MANAGEMENT
Patient using insulin pump (CSII)
Assessment should include blood glucose, blood/urine ketones,  +/- venous/arterial pH
Patient in diabetic 
ketoacidosis (DKA)
Start standard fixed rate 
insulin infusion using 
local DKA protocol.
 Remove CSII and 
tubing if possible. 
Refer to Diabetes team 
If CSII and tubing 
removed, give to relative 
for safe-keeping
If not possible, place 
with patient effects and 
document location
CSII cost ~ £4000 
to replace
Patient hypoglycaemic 
BG< 4mmol/l
Patient well enough to 
manage CSII on their own
Not in DKA or 
hypoglycaemic, but unwell 
or not eating / drinking 
or unable to manage 
pump independently
Hypoglycaemia 
persists despite 
2 rounds of hypo 
treatment
Hypoglycaemia 
successfully 
treated and 
BG>4mmol/l
Re-start CSII
Patient to review settings 
with Diabetes team
Hypoglycaemia treatment 
as per local guidelines
Remove (or pause) CSII  
(subcutaneous cannula may be 
left in-situ for upto 3 days)
Continue CSII but review 
1-2 hourly as appropriate
Start alternative 
insulin (IV/SC). 
Remove CSII and 
tubing if possible. 
Refer to Diabetes team
013
GUIDELINES FOR MANAGING CONTINUOUS SUBCUTANEOUS INSULIN 
INFUSION (CSII, OR ‘INSULIN PUMP’) THERAPY IN HOSPITALISED PATIENTS
CLINICAL GUIDELINE 
• Continue on CSII 
through procedure at 
usual basal rates. 
• Ensure cannula sited 
away from operative site 
and pump accessible 
to healthcare team.
• Monitor blood glucose 
at least hourly.
APPENDIX 2: CSII MANAGEMENT FOR ELECTIVE SURGICAL PROCEDURES UNDER SEDATION 
OR ANAESTHESIA
• If blood glucose<4, follow local hypoglycaemia protocol; re-test every 10-15 mins. Post hypo recovery, test glucose  
every 30 min until end of procedure
• Leave CSII in place and  do not attempt to adjust settings 
• If CSII alarms during procedure, don’t try to rectify; leave CSII in place, monitor blood glucose every 30mins.
• If alarm becomes intrusive, or patient has more than one hypo, remove  CSII and tubing (do not attempt to switch off 
CSII), Label CSII & store in secure place. Start VRII.  
Elective procedure  
without sedation
Minor procedures under 
general anaesthetic or sedation
(<2 hours and expected to 
eat/drink within 2-3hrs)
Blood glucose in acceptable 
range (4-12mmol/l)?
(if not, then treat. If following 
treatment, blood glucose does 
not return to and remain in 
acceptable range, then remove 
CSII and switch to VRII)
Major surgical procedure (>2 
hours duration, or where 
they are likely to miss more 
than one meal) or surgery 
requiring diathermy
Ask patient to remove CSII 
just before going to  theatre.
Label CSII & store 
in secure place
Start standard variable 
rate IV insulin infusion 
(VRII) immediately
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APPENDIX 3: WOMEN USING CSII ADMITTED IN LABOUR OR FOR ELECTIVE CAESAREAN SECTION 
BG < 4
Treat hypoglycaemia as 
per hospital protocol
Following one 
unexplained 
hypoglycaemia, ask 
the woman to reduce 
basal rate by 25 -50% 
using a temporary 
basal rate setting
If further episodes of 
hypoglycaemia despite 
original reduction, 
suggest further 
reduction in basal 
rate by another 25%. 
Post-delivery, patient/ 
partner to reduce basal 
rates back to pre-
pregnancy settings, or 
by 50% if CSII started 
during pregnancy
Continue at this 
basal rate for the 
rest of labour
Patient/ partner happy to continue on 
CSII during labour/ delivery?
Continue CSII on current settings
Insert IV cannula in case IV insulin/fluids required
Measure capillary 
blood glucose hourly
Target BG between 
4-7mmol/l
Target BG between 
4-7mmol/l
Continue CSII
BG > 7
Patient/partner to 
deliver correction 
dose using CSII
Recheck BG  1 hour later
BG 4- 7
Switch to standard  
IV insulin protocol
Remove CSII/
tubing and place in 
suitable container
SC cannula may 
remain in-situ
BG > 7
Give another 
correction bolus
If BG > 7 on 2 
consecutive  hourly 
readings despite 2 
correction doses 
then Switch to 
standard  IV insulin 
protocol (remove CSII/
tubing and place in 
suitable container)
Continue CSII
YES
NO
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APPENDIX 4: COMMONLY USED PUMPS & ASSOCIATED CONSUMABLES
Animas
• AA batteries
• Infusion sets
• Cannulas
Tech support: 0800 0556606
Medtronic Paradigm veo
• Contour Next test 
strips
• AAA Batteries
• Infusion set
• Cannula
Tech support: 01923 205167
Accu-chek combo:
• Test strips
• Cartridges
• Infusion set
• AA & AAA batteries
Tech support: 0800 7312291
Accu-chek Insight
 q Pre-filled cartridge. 
Only uses 1.6ml 
Novorapid pump cart
• Infusion sets
• Cannula
• AAA batteries
Tech support: 0800 7312291
Mylife Omnipod
• Abbott freestyle  
test strips
• Alkaline AAA batteries 
for hand-set
• Pod (syringe and 
needle inside pod)
Tech support: 08448 567820
Cellnovo
• Consists of 2 pumps, 
each lasting 3 days)
• Rechargeable pump & 
hand-set
• Charging dock
• One-touch test strips
Tech support: 0203 0581250
Medtronic 640g
• Contour Next test 
strips
• Infusion set
• Cannula
• AA lithium batteries
Tech support: 01923 205167
 q Information subject to change but correct at time of printing.
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